FDA Approved: ENTRESTO — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for ENTRESTO (sacubitril/valsartan) from Novartis Pharmaceuticals, resulting in changes to its label.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Entresto (sacubitril/valsartan)

Snippet

SUPPL AP for ENTRESTO (SACUBITRIL AND VALSARTAN)